The effects of isoflavone supplementation in the treatment of non atypical endometrial hyperplasia

The effects of isoflavone supplementation compared with placebo on endometrial histology and serum estradiol levels in premenopausal women with non atypical endometrial hyperplasia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200531047614N3

Enrollment

100

Registered

2021-01-20

Start date

2020-05-21

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non atypical endometrial hyperplasia. Endometrial hyperplasia

Interventions

Intervention 1: Intervention group: Isoflavone 50 mg Tablet (Goldaru Pharmaceutical Company, Tehran, Iran), orally, once a day, for 3 months. Intervention 2: Control group: Placebo Tablet (Goldaru Pha

Eligibility

Sex/Gender

Female

Age

30 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women aged 30 to 45 years who are diagnosed with non atypical endometrial hyperplasia

Exclusion criteria

Exclusion criteria: Those taking any hormonal medicine within 6 months prior to enrollment in the study Patients with focal endometrial lesions atypical endometrial hyperplasia Women with congenital uterine anomalies Menopause women Hypersensitivity to soybean products. Unwillingness to cooperate.

Design outcomes

Primary

Measure	Time frame
Endometrial histology. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Biopsy.	—

Secondary

Measure	Time frame
Serum estradiol levels. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Elisa.;Drug side-effects. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Zahra Vahedpour

Kashan University of Medical Sciences

zahravahedpoor@gmail.com+98 31 5554 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026